Investigators found no substantial increased risk for greater fine motor deficits or ADHD traits in offspring exposed to benzodiazepines or hypnotics at different gestational time points or for a longer duration.
Cognitive behavioral therapy shows promise promoting sleep in patients with schizophrenia.
The Food and Drug Administration (FDA) has approved a new cranial electrotherapy stimulator (CES) device for the treatment of anxiety, depression, and insomnia.
Higher-than-recommended dosages were commonly prescribed to women who were new zolpidem users.
Eisai and Imbrium Therapeutics announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lemborexant, an investigational insomnia treatment.
Symptoms of depression and PTSD may be increased in veterans with insomnia, which may be associated with an increased risk for suicidal behavior.
The authors argue that identifying and treating sleep disorders during early stages may have a positive impact on outcomes in psychiatric patients.
Nightmares are frequently comorbid with other sleep and mental health disorders in US military personnel.
Elderly patients have a higher prevalence of chronic pain than younger adults.
Insomnia for survivors of breast cancer was improved using ai chi chih as cognitive behavioral therapy.
